NL300995I2 - Combinatie van glycopyrronium, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of ester, in het bijzonder glycopyrronium bromide, en formoterol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of ester, in het bijzonder formoterol fumaraat dihydraat - Google Patents

Combinatie van glycopyrronium, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of ester, in het bijzonder glycopyrronium bromide, en formoterol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of ester, in het bijzonder formoterol fumaraat dihydraat Download PDF

Info

Publication number
NL300995I2
NL300995I2 NL300995C NL300995C NL300995I2 NL 300995 I2 NL300995 I2 NL 300995I2 NL 300995 C NL300995 C NL 300995C NL 300995 C NL300995 C NL 300995C NL 300995 I2 NL300995 I2 NL 300995I2
Authority
NL
Netherlands
Prior art keywords
ester
optionally
pharmaceutically acceptable
acceptable salt
glycopyrronium
Prior art date
Application number
NL300995C
Other languages
English (en)
Dutch (nl)
Other versions
NL300995I1 (enExample
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300995(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of NL300995I1 publication Critical patent/NL300995I1/nl
Publication of NL300995I2 publication Critical patent/NL300995I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1025—Respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
NL300995C 2009-05-29 2019-06-14 Combinatie van glycopyrronium, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of ester, in het bijzonder glycopyrronium bromide, en formoterol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of ester, in het bijzonder formoterol fumaraat dihydraat NL300995I2 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18256509P 2009-05-29 2009-05-29
US25817209P 2009-11-04 2009-11-04
US30936510P 2010-03-01 2010-03-01
US34553610P 2010-05-17 2010-05-17
PCT/US2010/036676 WO2010138884A2 (en) 2009-05-29 2010-05-28 Compositions, methods & systems for respiratory delivery of two or more active agents

Publications (2)

Publication Number Publication Date
NL300995I1 NL300995I1 (enExample) 2019-06-24
NL300995I2 true NL300995I2 (nl) 2019-10-29

Family

ID=42269864

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300995C NL300995I2 (nl) 2009-05-29 2019-06-14 Combinatie van glycopyrronium, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of ester, in het bijzonder glycopyrronium bromide, en formoterol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of ester, in het bijzonder formoterol fumaraat dihydraat

Country Status (31)

Country Link
US (12) US8808713B2 (enExample)
EP (6) EP2435023B1 (enExample)
JP (10) JP5873013B2 (enExample)
KR (7) KR101976107B1 (enExample)
CN (6) CN102458364B (enExample)
AR (3) AR076806A1 (enExample)
AU (3) AU2010253776B2 (enExample)
BR (3) BRPI1011220B1 (enExample)
CA (3) CA2763941A1 (enExample)
CY (8) CY1118040T1 (enExample)
DK (6) DK3111926T3 (enExample)
ES (6) ES2592536T3 (enExample)
FR (1) FR19C1040I2 (enExample)
HR (6) HRP20161102T1 (enExample)
HU (8) HUE047834T2 (enExample)
IL (3) IL216466B (enExample)
LT (8) LT2435025T (enExample)
LU (2) LUC00124I2 (enExample)
ME (1) ME03631B (enExample)
MX (5) MX350164B (enExample)
NL (1) NL300995I2 (enExample)
NO (2) NO2019026I1 (enExample)
PH (1) PH12017500778A1 (enExample)
PL (6) PL3106149T3 (enExample)
PT (6) PT2435023T (enExample)
RU (5) RU2580315C3 (enExample)
SI (6) SI2435025T1 (enExample)
SM (6) SMT202000108T1 (enExample)
TW (9) TWI546094B (enExample)
WO (3) WO2010138862A2 (enExample)
ZA (4) ZA201108275B (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003220125B2 (en) 2002-03-20 2006-06-15 Mannkind Corporation Inhalation apparatus
KR101273120B1 (ko) 2004-08-20 2013-06-13 맨카인드 코포레이션 다이케토피페라진 합성의 촉매 작용
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
US10002325B2 (en) 2005-03-30 2018-06-19 Primal Fusion Inc. Knowledge representation systems and methods incorporating inference rules
CN102614131A (zh) 2005-09-14 2012-08-01 曼金德公司 以提高结晶微粒表面对活性试剂的亲和力为基础的药物配制方法
WO2007098500A2 (en) 2006-02-22 2007-08-30 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN104491962B (zh) 2008-06-13 2018-10-23 曼金德公司 干粉吸入器和用于药物输送的系统
ES2904623T3 (es) 2008-06-20 2022-04-05 Mannkind Corp Aparato interactivo para establecer un perfil en tiempo real de esfuerzos de inhalación
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
BRPI1011220B1 (pt) * 2009-05-29 2020-03-10 Pearl Therapeutics, Inc. Composição farmacêutica administrável a partir de um inalador de dose medida compreendendo um meio de suspensão compreendendo um propelente, duas ou mais espécies diferentes de partículas de agente ativo e uma ou mais espécies de partículas respiráveis em suspensão
EP2582421A1 (en) * 2010-06-21 2013-04-24 MannKind Corporation Dry powder drug delivery system and methods
US10474647B2 (en) 2010-06-22 2019-11-12 Primal Fusion Inc. Methods and devices for customizing knowledge representation systems
US8925726B2 (en) 2011-04-01 2015-01-06 Mannkind Corporation Blister package for pharmaceutical cartridges
CN103687483A (zh) * 2011-05-17 2014-03-26 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
CN105106200A (zh) * 2011-05-17 2015-12-02 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
AU2013246926B2 (en) * 2012-04-13 2016-07-21 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
BR112015000529B1 (pt) 2012-07-12 2022-01-11 Mannkind Corporation Inalador de pó seco
CN102872027B (zh) * 2012-09-18 2014-03-12 刘晓忠 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备
KR102154104B1 (ko) * 2013-01-28 2020-09-09 인코젠 쎄라퓨틱스 프라이빗 리미티드 로플루밀라스트 n- 옥사이드의 흡입에 의한 자가면역, 호흡 및 염증성 장애의 치료방법
JP2016506947A (ja) * 2013-01-31 2016-03-07 プロソニックス リミテッド 吸入療法において使用するのに適する多成分結晶粒子を含む医薬組成物
GB201301721D0 (en) * 2013-01-31 2013-03-20 Prosonix Ltd Pharmaceutical Preparations
DK2964199T3 (da) * 2013-03-04 2020-06-15 Besins Healthcare Lu Sarl Tørre farmaceutiske sammensætninger omfattende aktivstof-nanopartikler bundet til bærerpartikler
BR112015020443A8 (pt) * 2013-03-14 2019-11-12 Novartis Ag formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica
TR201902687T4 (tr) * 2013-03-15 2019-03-21 Pearl Therapeutics Inc İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler.
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
WO2014190204A1 (en) * 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
PT3054920T (pt) * 2013-10-07 2021-03-23 Teva Branded Pharmaceutical Products R&D Inc Inalador de pó seco
HK1212903A1 (zh) * 2013-11-22 2016-06-24 Teva Branded Pharmaceutical Products R & D, Inc. 可吸入藥物
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
CN104188941B (zh) * 2014-09-02 2016-11-16 重庆和平制药有限公司 一种制备盐酸克仑特罗吸入粉雾剂的方法
EP3200799A4 (en) * 2014-10-01 2018-05-30 ALS Mountain LLC Pharmaceutical composition comprising aspirin, metformin, and serotonin with non-ionic surfactant
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
WO2017108917A1 (en) 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
CN108883079A (zh) * 2016-03-15 2018-11-23 广东东阳光药业有限公司 喷雾剂、喷雾装置以及喷雾组件
WO2017201003A1 (en) * 2016-05-17 2017-11-23 Mayo Foundation For Medical Education And Research Materials and methods for treating chronic cough
AU2017290610A1 (en) 2016-06-30 2018-11-15 Philip Morris Products S.A. Nicotine particles
EP3915555B1 (en) 2016-09-19 2023-06-28 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising glycopyrrolate
JP6906947B2 (ja) * 2016-12-22 2021-07-21 キヤノン株式会社 画像処理装置、撮像装置、画像処理方法およびコンピュータのプログラム
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
CN107243080B (zh) * 2017-06-21 2021-11-12 上海上药信谊药厂有限公司 一种吸入式气雾剂、其原料组合物及制备方法
CA3078209A1 (en) * 2017-10-09 2019-04-18 Pearl Therapeutics, Inc. Drug delivery systems and related methods
JP7372727B2 (ja) 2017-11-20 2023-11-01 三菱重工業株式会社 系統運用者側コンピュータ、発電事業者側コンピュータ、電力システム、制御方法及びプログラム
WO2020070620A2 (en) * 2018-10-01 2020-04-09 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
JP7090941B2 (ja) * 2018-10-02 2022-06-27 学校法人 名城大学 吸入粉末剤、その評価方法及びその用途
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法
WO2020229966A1 (en) * 2019-05-10 2020-11-19 Glenmark Pharmaceutical Limited Stable aerosol composition for inhalation comprising glycopyrronium
CN112137957B (zh) 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN112804991B (zh) * 2019-06-27 2022-03-11 广州谷森制药有限公司 含富马酸福莫特罗和阿地溴铵的可吸入溶液制剂
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
GEP20247642B (en) * 2020-02-20 2024-07-10 Chiesi Farm Spa Pressurised metered dose inhalers comprising buffered pharmaceutical formulation
PT3962455T (pt) * 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
WO2022016068A1 (en) * 2020-07-16 2022-01-20 Tbd Pharma Llc Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections
CA3179014A1 (en) 2020-09-29 2022-04-07 iPharma Labs, Inc. Liquid formulations of indacaterol
TW202241410A (zh) * 2021-01-08 2022-11-01 大陸商江蘇恒瑞醫藥股份有限公司 可經由定量吸入器遞送的藥物組合物
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
WO2023283441A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
EP4236921A1 (en) 2021-11-25 2023-09-06 Orexo AB Pharmaceutical composition comprising adrenaline
US20250057764A1 (en) 2021-12-20 2025-02-20 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
EP4514358A1 (en) 2022-04-28 2025-03-05 AstraZeneca AB Combination of albuterol and budesonide for the treatment of asthma
WO2024206662A1 (en) * 2023-03-30 2024-10-03 Aerorx Therapeutics Llc Liquid formulations of indacaterol and glycopyrronium
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用
US20250268914A1 (en) * 2024-02-26 2025-08-28 Honeywell International Inc. Fluticasone delivery compositions, devices and methods
CN118787617A (zh) * 2024-09-14 2024-10-18 苏州易合医药有限公司 一种吸入粉剂及其制备方法

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (enExample) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
US4335121A (en) * 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
EP0057401B1 (en) * 1981-02-02 1984-08-01 Schering Corporation Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
FR2651678B1 (fr) 1989-09-08 1992-04-30 Glaxo Group Ltd Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
PL165803B1 (pl) 1990-09-10 1995-02-28 Schering Corp Sposób wytwarzania nowego monohydratu 9a, 21-dichloro-16-a metylo-1,4-pregnadieno-11 ß , 17a-diolo-3,20-diono-17-(2’furanokarboksylanu) PL PL PL PL
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
US5635563A (en) 1991-04-01 1997-06-03 Tomoegawa Paper Co., Ltd. Polyaniline derivatives and their production process
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
HU0004452D0 (enExample) 1991-12-18 2001-01-29 Astra Ab
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5849263A (en) 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
EP0731688B1 (en) 1993-12-02 2003-03-05 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
EP0742888B1 (en) 1994-02-09 1998-04-22 Kinerton Limited Process for drying a material from solution
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
KR100428914B1 (ko) * 1994-12-22 2004-06-16 아스트라제네카 악티에볼라그 에어로졸약물제제
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
ATE287703T1 (de) 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
DE19614421C2 (de) 1996-04-12 1999-12-16 Biovision Gmbh Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff
GB9610821D0 (en) 1996-05-23 1996-07-31 Glaxo Wellcome Inc Metering apparatus
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
PT1371645E (pt) * 1996-11-11 2013-05-21 Meda Pharma Gmbh & Co Kg Utilização de (3s,2¿r)-glicopirrónio como produto farmacêutico
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
ATE415149T1 (de) 1997-03-20 2008-12-15 Schering Corp Dosierungsform eines pulveragglomerates
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
EA003665B1 (ru) 1997-09-29 2003-08-28 Нектар Терапьютикс Перфорированные микрочастицы и способ их использования
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
JP4422894B2 (ja) 1998-03-05 2010-02-24 千寿製薬株式会社 眼底組織細胞障害による疾患の予防および治療用医薬組成物
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6260549B1 (en) * 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DE59911149D1 (de) 1998-07-24 2004-12-30 Jago Res Ag Muttenz Medizinische aerosolformulierungen
AU749697B2 (en) * 1998-08-04 2002-07-04 Jagotec Ag Medicinal aerosol formulations
PT1131059E (pt) * 1998-11-13 2003-07-31 Jago Res Ag Po seco para inalacao
GB9912639D0 (en) * 1999-05-28 1999-07-28 Britannia Pharmaceuticals Ltd Improvements in and relating to treatment of respiratory conditions
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
NZ512383A (en) 1998-12-22 2003-05-30 Univ North Carolina Use of osmotic agents in the treatment of airway diseases and for the delivery of airway drugs
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
PT1158958E (pt) 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
JP2002541183A (ja) 1999-04-14 2002-12-03 グラクソ グループ リミテッド 医薬用エアゾール製剤
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
JP4327394B2 (ja) 1999-06-30 2009-09-09 ネクター セラピューティクス 乾燥粉末を調製するための噴霧乾燥法
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
PT102343B (pt) * 1999-08-02 2003-11-28 Hovione Farmaciencia Sa Processo para a preparacao de furoato mometasona
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
PT1666028E (pt) * 1999-10-29 2010-06-15 Novartis Ag Composições de pós anidros com melhor dispersividade
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PL358375A1 (en) 2000-04-13 2004-08-09 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
AU6124601A (en) 2000-05-10 2001-11-20 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
WO2002014293A1 (en) 2000-08-15 2002-02-21 Carsten Berg Quaternary ammonium salts of 1,2-benzisothiazolin-3-one. preparation and use as biocides
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) * 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
AU2002222118A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
US8048451B2 (en) * 2000-11-30 2011-11-01 Vectura Limited Pharmaceutical compositions for inhalation
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
CA2433335C (en) 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
IL157580A0 (en) * 2001-03-20 2004-03-28 Glaxo Group Ltd Inhalation drug combination
RU2294737C2 (ru) * 2001-03-30 2007-03-10 Яготек Аг Медицинские аэрозольные составы
WO2002078761A1 (fr) * 2001-03-30 2002-10-10 Laboratoires Genevrier Neo-tissu cartilagineux greffable
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
DE10202940A1 (de) * 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
DE10214264A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
WO2004014293A2 (en) * 2002-06-12 2004-02-19 Epigenesis Pharmaceuticals, Inc. Combination of anti-muscarinic agents and non-glucocorticoid steroids
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
DE10237739A1 (de) 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
CA2495689A1 (en) 2002-08-23 2004-03-04 Schering Corporation Pharmaceutical compositions
CN1694689A (zh) 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
WO2004035417A1 (en) * 2002-10-15 2004-04-29 Cryovac, Inc. A process for triggering, storing, and distributing an oxygen scavenger, and a stored oxygen scavenger
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
DE10323966A1 (de) 2003-05-27 2004-12-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
KR101511196B1 (ko) 2003-05-28 2015-04-10 노바르티스 아게 아미노산 및/또는 인지질로 부분 또는 완전 코팅된 수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의 분무 건조법
EP1638567B1 (en) 2003-06-16 2012-02-29 Nycomed GmbH Composition comprising a pulmonary surfactant and sildenafil for the treatment of lung diseases
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
DE602004019096D1 (de) 2003-07-28 2009-03-05 Boehringer Ingelheim Pharma Medikamente zur inhalation mit betamimetika und einem anticholinergikum
NZ545443A (en) 2003-07-29 2010-04-30 Boehringer Ingelheim Int Combination of an aclidinium salt known as 3-(2-hydroxy-2,2-dithiophen-2-yl-acetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane and a steroid and its use to treat respiratory disorders by inhalation
MXPA06001047A (es) 2003-07-29 2006-04-24 Boehringer Ingelheim Int Medicamentos para inhalacion que comprenden betamimeticos y un anticolinergico.
CA2534120C (en) 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
EP1925293A3 (en) 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
CN100569760C (zh) * 2003-11-21 2009-12-16 施万制药 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
KR20070007075A (ko) * 2003-12-31 2007-01-12 사이덱스 인크 술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형
DK1713473T3 (da) * 2004-02-06 2013-06-17 Meda Pharma Gmbh & Co Kg Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD
ATE399027T1 (de) 2004-02-06 2008-07-15 Meda Pharma Gmbh & Co Kg Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
WO2005077339A1 (en) * 2004-02-10 2005-08-25 E.I. Dupont De Nemours And Company Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon comprising milling the said sol, then transfert it into a canister
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
RU2389477C2 (ru) * 2004-06-18 2010-05-20 Новартис Ваксинз Энд Дайагностикс Инк. Способы лечения эндобронхиальных заболеваний
GB0426301D0 (en) 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
US20060140873A1 (en) 2004-12-27 2006-06-29 Chang Heng W Aerosol pharmaceutical compositions
JP2008534480A (ja) 2005-03-24 2008-08-28 ソーセイ アールアンドディ リミテッド グリコピロニウム塩およびそれらの治療的使用
MX2007012084A (es) 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
CA2607391A1 (en) 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP1893203A2 (en) 2005-05-31 2008-03-05 Boehringer Ingelheim International GmbH Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
CA2611907A1 (en) 2005-06-17 2006-12-21 Boehringer Ingelheim International Gmbh Mrp iv inhibitors for the treatment of respiratory diseases
US8475845B2 (en) 2005-07-15 2013-07-02 Map Pharmaceuticals, Inc. Method of particle formation
CN103462943A (zh) 2005-07-15 2013-12-25 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
CN100560598C (zh) * 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
AT502396B1 (de) 2005-09-01 2007-03-15 Montanuniv Leoben Verfahren zum abtrennen von verunreinigungen aus einsatzstoffen
GB0523655D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
DE602006008665D1 (de) 2005-12-21 2009-10-01 Meda Pharma Gmbh & Co Kg Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
EP1981475A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations
WO2007134964A1 (en) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0614621D0 (en) * 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP2327403A3 (en) * 2007-02-19 2011-08-31 Cipla Limited Pharmaceutical combinations of at least two bronchodilators
EP1964564A1 (en) * 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
EP2036572A1 (en) 2007-09-04 2009-03-18 Novo Nordisk A/S Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle
CN101317821B (zh) * 2007-11-15 2012-01-04 陈晓东 适用于肺部给药的超细干粉颗粒及其制备方法
KR20100099281A (ko) * 2007-12-13 2010-09-10 노파르티스 아게 유기 화합물
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
FR2940162B1 (fr) 2008-12-22 2011-02-25 Boehm & Cie Ets Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
BRPI1011220B1 (pt) * 2009-05-29 2020-03-10 Pearl Therapeutics, Inc. Composição farmacêutica administrável a partir de um inalador de dose medida compreendendo um meio de suspensão compreendendo um propelente, duas ou mais espécies diferentes de partículas de agente ativo e uma ou mais espécies de partículas respiráveis em suspensão
PH12012501792A1 (en) 2010-04-01 2012-12-10 Chiesi Farm Spa Process for preparing carrier particles for dry powders for inhalation
EP2627317A4 (en) 2010-10-15 2014-08-20 Glaxo Group Ltd MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE
EP2749284A3 (en) 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and carmoterol
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
CN103687483A (zh) 2011-05-17 2014-03-26 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
WO2014190204A1 (en) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents

Also Published As

Publication number Publication date
ZA201108275B (en) 2023-04-26
KR101926060B1 (ko) 2018-12-06
TWI695723B (zh) 2020-06-11
KR101748892B1 (ko) 2017-06-19
HUE047803T2 (hu) 2020-05-28
KR20120034631A (ko) 2012-04-12
LTC2435025I2 (lt) 2021-02-10
LUC00124I1 (enExample) 2019-06-13
IL216468A0 (en) 2012-01-31
KR20190049943A (ko) 2019-05-09
HRP20200260T1 (hr) 2020-05-29
CN107669664A (zh) 2018-02-09
CN102458364A (zh) 2012-05-16
PL3106149T3 (pl) 2020-06-01
AR076621A1 (es) 2011-06-22
US20190038548A1 (en) 2019-02-07
IL216467B (en) 2018-12-31
JP5873012B2 (ja) 2016-03-01
KR20170070274A (ko) 2017-06-21
PL3111926T3 (pl) 2020-06-29
HRP20200298T1 (hr) 2020-06-12
EP2435023B1 (en) 2016-07-06
CN107412212A (zh) 2017-12-01
WO2010138868A2 (en) 2010-12-02
JP2015199735A (ja) 2015-11-12
MX393243B (es) 2025-03-24
JP2012528199A (ja) 2012-11-12
DK3106149T3 (da) 2020-02-24
DK3111926T3 (da) 2020-03-02
ZA201208100B (en) 2013-07-31
RU2020102859A (ru) 2021-07-26
DK3111927T3 (da) 2020-03-09
JP2019108369A (ja) 2019-07-04
PH12017500778A1 (en) 2018-01-22
HK1244669A1 (zh) 2018-08-17
SI3111927T1 (sl) 2020-08-31
EP3106149A1 (en) 2016-12-21
PT2435023T (pt) 2016-10-14
RU2015151358A (ru) 2019-01-16
CA2763936A1 (en) 2010-12-02
RU2713404C2 (ru) 2020-02-05
HRP20200166T1 (hr) 2020-05-15
US20170071850A1 (en) 2017-03-16
JP5873013B2 (ja) 2016-03-01
SI3106149T1 (sl) 2020-07-31
RU2751771C2 (ru) 2021-07-16
WO2010138884A3 (en) 2011-04-21
ES2774391T3 (es) 2020-07-20
RU2580315C3 (ru) 2021-06-18
NL300995I1 (enExample) 2019-06-24
US20150017247A1 (en) 2015-01-15
JP6492124B2 (ja) 2019-03-27
JP5823383B2 (ja) 2015-11-25
PT3106149T (pt) 2020-02-19
WO2010138868A3 (en) 2011-04-28
PL3111927T3 (pl) 2020-06-29
CA2763936C (en) 2017-10-03
MX2011012684A (es) 2012-05-23
EP2435025A2 (en) 2012-04-04
TW202114642A (zh) 2021-04-16
HK1169307A1 (zh) 2013-01-25
CY2019031I2 (el) 2019-11-27
AU2010253770B9 (en) 2015-02-12
US9463161B2 (en) 2016-10-11
CN102753152A (zh) 2012-10-24
KR20120026075A (ko) 2012-03-16
CY2021012I2 (el) 2021-10-15
MX2011012783A (es) 2012-06-28
SMT201600329B (it) 2016-11-10
EP2435023A2 (en) 2012-04-04
US20180125776A1 (en) 2018-05-10
JP6348645B2 (ja) 2018-06-27
TWI646980B (zh) 2019-01-11
BRPI1011220B1 (pt) 2020-03-10
EP3106149B1 (en) 2019-11-20
CA2763941A1 (en) 2010-12-02
PL2435023T3 (pl) 2017-06-30
LT2435025T (lt) 2016-09-26
IL216466A0 (en) 2012-01-31
RU2016117972A3 (enExample) 2019-09-27
US20210186861A1 (en) 2021-06-24
HK1169027A1 (zh) 2013-01-18
BRPI1011229A2 (pt) 2016-03-15
AR076806A1 (es) 2011-07-06
US20110132357A1 (en) 2011-06-09
LT3106149T (lt) 2020-03-10
SMT202000108T1 (it) 2020-03-13
AU2010253776A1 (en) 2011-11-24
WO2010138862A3 (en) 2011-04-14
PT2435024T (pt) 2016-10-13
LT2435023T (lt) 2016-09-26
RU2015151358A3 (enExample) 2019-07-29
HK1169026A1 (zh) 2013-01-18
RU2016107464A (ru) 2018-11-22
LT2435024T (lt) 2016-09-26
DK2435025T3 (en) 2016-10-24
AU2010253770B2 (en) 2014-12-11
TW201700123A (zh) 2017-01-01
CN102458364B (zh) 2016-11-02
CN102596176B (zh) 2017-09-19
TW201919730A (zh) 2019-06-01
LTPA2021511I1 (enExample) 2021-06-25
TWI717511B (zh) 2021-02-01
RU2011154083A (ru) 2013-07-10
TW201109051A (en) 2011-03-16
MX350163B (es) 2017-08-29
AU2010253770A1 (en) 2011-11-24
US8808713B2 (en) 2014-08-19
RU2011152960A (ru) 2013-07-10
LUC00208I2 (enExample) 2022-10-07
JP2018008942A (ja) 2018-01-18
HRP20161098T1 (hr) 2016-10-21
US10716753B2 (en) 2020-07-21
ES2589135T3 (es) 2016-11-10
CY1122732T1 (el) 2021-03-12
DK2435024T3 (en) 2016-10-24
SMT201600327B (it) 2016-11-10
PL2435024T3 (pl) 2017-01-31
BRPI1011220A2 (pt) 2016-03-15
HUE047834T2 (hu) 2020-05-28
IL216467A0 (en) 2012-01-31
KR101976107B1 (ko) 2019-05-09
SMT201600326B (it) 2016-11-10
JP6876734B2 (ja) 2021-05-26
JP2012528792A (ja) 2012-11-15
US20110023876A1 (en) 2011-02-03
ME03631B (me) 2020-07-20
HRP20161102T1 (hr) 2016-11-04
EP2435025B1 (en) 2016-07-06
CY2021012I1 (el) 2021-10-15
MX2011012685A (es) 2012-06-12
TWI792140B (zh) 2023-02-11
SMT202000109T1 (it) 2020-03-13
CN102596176A (zh) 2012-07-18
MX350164B (es) 2017-08-29
PT3111926T (pt) 2020-02-28
LTPA2019014I1 (lt) 2019-07-10
CY1122749T1 (el) 2021-03-12
JP2018048150A (ja) 2018-03-29
BRPI1011508A2 (pt) 2016-03-22
AU2010253950A1 (en) 2011-12-08
US20250009652A1 (en) 2025-01-09
TW201642836A (zh) 2016-12-16
SI2435023T1 (sl) 2016-10-28
KR20120015334A (ko) 2012-02-21
CY2019031I1 (el) 2019-11-27
ES2592536T3 (es) 2016-11-30
KR20170104003A (ko) 2017-09-13
CN107669664B (zh) 2020-07-10
SI2435024T1 (sl) 2016-10-28
TWI707700B (zh) 2020-10-21
TWI546094B (zh) 2016-08-21
JP2015187108A (ja) 2015-10-29
AR076807A1 (es) 2011-07-06
TW201936174A (zh) 2019-09-16
IL216466B (en) 2018-08-30
EP3111927B1 (en) 2019-12-11
HUE047823T2 (hu) 2020-05-28
ES2774367T3 (es) 2020-07-20
CY1122807T1 (el) 2021-05-05
LUC00124I2 (enExample) 2019-12-27
RU2016117972A (ru) 2018-10-29
US20110132356A1 (en) 2011-06-09
HUE031229T2 (en) 2017-06-28
CY1118030T1 (el) 2017-05-17
ZA201208101B (en) 2013-07-31
CN105193773B (zh) 2018-12-11
TW201808372A (zh) 2018-03-16
HUS2100018I1 (hu) 2021-06-28
AU2010253950C1 (en) 2015-09-17
HRP20161101T1 (hr) 2016-11-04
NO2021019I1 (no) 2021-05-12
FR19C1040I2 (fr) 2020-07-31
LT3111927T (lt) 2020-03-25
EP3111927A1 (en) 2017-01-04
US20170112759A1 (en) 2017-04-27
WO2010138884A2 (en) 2010-12-02
EP2435024B1 (en) 2016-07-06
CN105193773A (zh) 2015-12-30
HK1247095A1 (zh) 2018-09-21
IL216468B (en) 2018-12-31
CY1118040T1 (el) 2017-05-17
RU2011154148A (ru) 2013-07-10
TWI633898B (zh) 2018-09-01
SI2435025T1 (sl) 2016-10-28
TW201109049A (en) 2011-03-16
BRPI1011229B1 (pt) 2020-10-13
ZA201208102B (en) 2013-09-25
RU2580315C2 (ru) 2016-04-10
HK1218867A1 (zh) 2017-03-17
FR19C1040I1 (enExample) 2020-07-31
DK2435023T3 (en) 2016-10-24
PL2435025T3 (pl) 2017-08-31
RU2016107464A3 (enExample) 2019-08-19
JP6189356B2 (ja) 2017-08-30
CN102753152B (zh) 2015-09-23
JP6169639B2 (ja) 2017-07-26
ES2772253T3 (es) 2020-07-07
AU2010253776B2 (en) 2015-01-22
WO2010138862A2 (en) 2010-12-02
JP2012528200A (ja) 2012-11-12
JP2017222706A (ja) 2017-12-21
US20110135737A1 (en) 2011-06-09
US20190307676A1 (en) 2019-10-10
LTC2435024I2 (enExample) 2022-06-27
MX377778B (es) 2025-03-11
CY1118034T1 (el) 2017-05-17
EP2435024A2 (en) 2012-04-04
EP3111926B1 (en) 2019-12-11
TWI539979B (zh) 2016-07-01
SI3111926T1 (sl) 2020-07-31
KR20180130602A (ko) 2018-12-07
RU2586297C2 (ru) 2016-06-10
TW201109050A (en) 2011-03-16
JP2016041713A (ja) 2016-03-31
CA2763939A1 (en) 2010-12-02
BRPI1011229B8 (pt) 2021-05-25
PT2435025T (pt) 2016-11-11
MX337126B (es) 2016-02-12
HUE029532T2 (en) 2017-03-28
LT3111926T (lt) 2020-03-25
TWI632926B (zh) 2018-08-21
EP3111926A1 (en) 2017-01-04
MX2020004077A (es) 2020-07-29
CN107412212B (zh) 2021-01-22
SMT202000077T1 (it) 2020-03-13
NO2019026I1 (no) 2019-06-13
AU2010253950B2 (en) 2014-12-04
HUE031283T2 (hu) 2017-07-28
ES2593429T3 (es) 2016-12-09
HUS1900031I1 (hu) 2019-07-29
PT3111927T (pt) 2020-03-03

Similar Documents

Publication Publication Date Title
NL300995I2 (nl) Combinatie van glycopyrronium, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of ester, in het bijzonder glycopyrronium bromide, en formoterol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of ester, in het bijzonder formoterol fumaraat dihydraat
NL301321I2 (nl) Delgocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat daarvan
NO2020018I1 (no) Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
NL301067I2 (nl) Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301299I2 (nl) Capivasertib, eventueel in de vorm van een farmaceutisch aanvaardbaar zout
NL301305I2 (nl) Vibegron of een farmaceutisch aanvaardbaar zout daarvan
NL301166I2 (nl) Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301033I2 (nl) Larotrectinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder larotrectinibsulfaat, met inbegrip van larotrectinibsulfaat monohydraat
NL301291I2 (nl) sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NO2025034I1 (no) Remdesivir or a pharmaceutically acceptable salt or ester thereof - forlengelse
NO2025011I1 (no) Erdafitinib or a pharmaceutically acceptable salt thereof or a solvate thereof
NO2019042I1 (no) Talazoparib, eventuelt i form av et farmasøytisk aksepterbart salt
NO2022033I1 (no) Rimegepant or a pharmaceutically acceptable salt thereof
NL301071I2 (nl) alpelisib of een farmaceutisch aanvaardbaar zout ervan
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
NO2020006I1 (no) upadacitinib or a pharmaceutically acceptable salt thereof
NL300909I2 (nl) Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301057I2 (nl) Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout
NL300980I1 (nl) Doravirine, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300971I2 (nl) Eravacycline, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301047I2 (nl) fosnetupitant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder fosnetupitantchloridehydrochloride
NL301304I2 (nl) aprocitentan of een farmaceutisch aanvaardbaar zout daarvan
HUS000509I2 (hu) Abemaciklib vagy egy gyógyászatilag elfogadható sója
NL300871I2 (nl) ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat
NL301043I2 (nl) Osilodrostat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van osilodrostatdiwaterstoffosfaat